Cancer Prevention Pharmaceuticals, Inc.

16 articles with Cancer Prevention Pharmaceuticals, Inc.

• Cancer Prevention Pharmaceuticals Announces NEJM Publication of Landmark Phase 3 Clinical Trial for Treatment of Familial Adenomatous Polyposis

  9/11/2020

  Cancer Prevention Pharmaceuticals, Inc. announced The New England Journal of Medicine has published results from its landmark FAP-310 Phase 3 clinical trial of CPP-1X/sul as a pharmaco-preventive treatment for adults with familial adenomatous polyposis.

• Cancer Prevention Pharmaceuticals Submits New Drug Application to the FDA for CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

  6/29/2020

  Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP). F

• Cancer Prevention Pharmaceuticals Submits EU Marketing Authorization Application for CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

  6/18/2020

  Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for CPP-1X/sul for treatment of adults with familial adenomatous polyposis (FAP

• Cancer Prevention Pharmaceuticals (CPP) Reports FAP Phase 3 Clinical Trial Results at Digestive Disease Week Conference

  6/20/2019

  Cancer Prevention Pharmaceuticals, Inc. (CPP) recently reported results from its pivotal Phase 3 trial of CPP-1X/sul for adults with familial adenomatous polyposis (FAP) at the Digestive Disease Week annual conference in San Diego.

• Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulindac in Patients with Familial Adenomatous Polyposis

  5/7/2019

  Full data to be presented in detail by CPP at Digestive Disease Week (DDW) conference on May 19, 2019 at 5:19 pm Pacific Time

• Cancer Prevention Pharmaceuticals Announces Last Patient Completes Phase 3 Trial Protocol of CPP-1X/sul for Familial Adenomatous Polyposis

  12/10/2018

  Analysis of data expected in early 2019

• Cancer Prevention Pharmaceuticals to Present at Piper Jaffray Healthcare Conference in NYC, November 28, 2018

  11/19/2018

  Company to highlight progress of Phase 3 trial of lead drug, CPP-1X/sul, for Familial Adenomatous Polyposis

• Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt

  8/13/2018

  License includes 50/50 profit share and additional payments of up to $185 million dependent on achieving clinical development and sales milestones, and subject to certain reductions.

• Cancer Prevention Pharma In Collaboration With The NCI And Vanderbilt University Medical Center Initiates Phase II Trial To Evaluate CPP-1X In Patients With High Risk Of Gastric Cancer

  7/17/2017

• Independent Data Monitoring Committee Recommends Continuation Of Cancer Prevention Pharma’ Phase III Trial For Familial Adenomatous Polyposis Patients

  6/12/2017

• Cancer Prevention Pharma Completes Target Enrollment In Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/Sulindac In Patients With Familial Adenomatous Polyposis

  4/4/2016

• Cancer Prevention Pharma Files for a $29 Million IPO

  12/29/2015

• Cancer Prevention Pharmaceuticals, Inc. Announces Appointment Of Jon S. Saxe To Its Board Of Directors

  7/23/2015

• Cancer Prevention Pharmaceuticals, Inc. And Tillotts Pharma AG Sign Licensing Agreement For CPP-1X/Sulindac In Europe And Japan

  1/10/2014

• Cancer Prevention Pharmaceuticals, Inc. Release: Phase 3 Familial Adenomatous Polyposis (FAP) Trial Now Open For Enrollment

  12/5/2013

• Cancer Prevention Pharmaceuticals, Inc. Announces Completion of Bridge Financing Round

  8/24/2011